Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0OMACI
ADC Name	Anti-IL13RA2-ADC
Synonyms	PF-06473811; anti-IL13RA2-Ab-AF680; IL13R2-AB08-v1010-hG1- (C)mcValCitPABC_Aur-06380101 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Melanoma [ICD11:2C30] Investigative
Drug-to-Antibody Ratio	3.2
Structure
	3D MOL	2D MOL
Antibody Name	Anti-IL13RA2 PF-06473811 mAb		Antibody Info
Antigen Name	Interleukin-13 receptor subunit alpha-2 (IL13RA2)		Antigen Info
Payload Name	Auristatin 0101		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Site-specific conjugated of maleimidocaproyl with cysteine free thiol via Michael addition.
Combination Type	Vc0101

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 29.6	%	A375 cells	Amelanotic melanoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.60% (Day 13)	High IL13RA2 expression (IL13RA2+++)
Method Description	2 x10⁶ A375 cells in 50% Cultrex basement membrane extract were injected subcutaneously in the flank of athymic nu/nu mice for FMT imaging or in the upper right shoulder for PET/CT imaging.
In Vivo Model	A375 xenograft model
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132

References

Ref 1	Targeting and pharmacology of an anti-IL13R2 antibody and antibody-drug conjugate in a melanoma xenograft model. MAbs. 2021 Jan-Dec;13(1):1958662.